Developing precise predictive models for pediatric acute myeloid leukemia (pAML) is crucial for bridging the preclinical gap in treatments for this rare disease. The use of patient-derived xenograft (PDX) models presents a promising avenue for advancing our understanding of pAML and addressing the challenge of chemotherapy resistance.
The Importance of PDX Models
Pediatric patients with AML exhibit significant biological and genetic differences compared to adults. This discrepancy necessitates the creation of tailored therapeutic agents to effectively combat their disease. PDX models have emerged as the gold standard for evaluating potential new treatments in a preclinical context, allowing researchers to more accurately mimic human tumor behavior.
These models involve transplanting human cancer cells into immunodeficient mice, enabling the replication of a human tumor within a living organism. The advantage of PDX models lies in their ability to retain the genetic complexity and heterogeneity of the original tumor, making them more predictive of patient responses to therapy than traditional cell line models.
Challenges in Developing PDX Models for Pediatric AML
Despite their success with various cancer types, developing PDX models for pediatric AML has proven to be a significant challenge. Factors contributing to these difficulties include a limited patient population, a shortage of specialized expertise in model generation, and inadequate financial incentives to pursue research for a rare disease.
Researchers at Texas Children’s Hospital at Baylor College of Medicine (TCH BCM) have recently made strides in overcoming these obstacles. By leveraging a large patient cohort and established banking protocols, they have successfully generated multiple pAML PDX models.
Methodology and Sample Collection
The samples utilized in this research were sourced from the Children’s Oncology Group (COG) biobank and from local patients diagnosed at TCH. Mice were procured from Jackson Laboratories and bred in-house. Two strains of immunodeficient mice, NSG and NSGS, were employed, with a preference for NSGS due to their commercial availability.
From a total of 174 samples collected from 154 patients, 49 successfully led to primary engraftment, while 26 were able to undergo serial transplantation. Notably, cells derived from pheresis products exhibited a higher likelihood of establishing stable PDX models, possibly due to the enrichment of these samples for KMT2A rearrangements.
Validation and Genetic Consistency
All PDX models underwent validation through short tandem repeat analysis. In a critical finding, next-generation sequencing revealed that the pAML PDX models maintained similar variant allele frequencies when compared to the original patient material. This is an important validation step, particularly given the common concern regarding the loss of subclonal populations during sample passage.
When patient samples were identified as harboring significant mutations or genetic abnormalities, efforts were made to trial these samples for engraftment in advanced mouse strains such as MISTRG or MISTRG6, when available.
Insights from Serial Transplantation Trials
Through their experimental procedures, the researchers discovered that only two of the 26 serially transplanted models (AML007 and AML008) were successfully maintained in the MISTRG strain of mice. This indicated that many genetic subtypes of pAML may not engraft effectively during the primary passage and struggle with serial transplantation.
The investigators hypothesized that the supportive conditions within the host microenvironment play a crucial role in the establishment and expansion of pAML. Ongoing work aims to optimize the engraftment process for these rarer pAML subtypes.
A Renewed Resource for Research
Overall, the models developed by the research team at TCH BCM have successfully addressed gaps in the preclinical pipeline, enabling the testing of promising new agents targeted at pAML. Their systematic approach has yielded a renewable resource that benefits researchers focused on pediatric AML both at TCH BCM and beyond.
Conclusion
The advancements in creating PDX models for pediatric AML mark a significant step forward in the quest for effective treatments. By providing a reliable platform for testing new therapies, these models hold the promise of accelerating the development of innovative treatments tailored specifically for young patients battling this challenging disease.
- PDX models are essential for understanding pediatric AML and improving treatment outcomes.
- Texas Children’s Hospital has successfully developed multiple pAML PDX models.
- Challenges in developing these models include limited patient availability and financial constraints.
- Validation of PDX models ensures the retention of genetic characteristics from patient tumors.
- Continued research aims to optimize the engraftment of rare subtypes, paving the way for breakthroughs in therapy.
Read more → www.ajmc.com